Karen M Ryan1, Ross Dunne1, Declan M McLoughlin2. 1. Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland; Department of Psychiatry, St. Patrick's University Hospital, Trinity College Dublin, Dublin, Ireland. 2. Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland; Department of Psychiatry, St. Patrick's University Hospital, Trinity College Dublin, Dublin, Ireland. Electronic address: d.mcloughlin@tcd.ie.
Abstract
BACKGROUND: Brain derived neurotrophic factor (BDNF) has been implicated in the pathophysiology of depression and the antidepressant response. Electroconvulsive therapy (ECT) is reported to increase BDNF levels in blood, though only a small number of studies have been conducted to date. OBJECTIVE: Our objectives were to: 1) compare plasma BDNF levels in medicated patients with depression and controls; 2) assess the effect of ECT on plasma BDNF levels in medicated patients with depression; 3) explore the relationship between plasma BDNF levels and the Val66Met (rs6265) BDNF polymorphism; and 4) examine the relationship between plasma BDNF levels and clinical symptoms and outcomes with ECT. METHODS: Plasma BDNF levels were analyzed in samples from 61 medicated patients with a major depressive episode and 50 healthy controls, and in patient samples following a course of ECT. Fifty-two samples from the depressed patient group were genotyped for the Val66Met BDNF polymorphism. RESULTS: There was no difference in plasma BDNF levels between the control and depressed groups, and there was no difference in plasma BDNF levels in patients following treatment with ECT. In line with previous reports, we show that, in medicated patients with depression, Met-carriers had higher plasma BDNF levels than Val-carriers, though genotype was not related to clinical response. We found no association between plasma BDNF levels and depression severity or the clinical response to ECT. CONCLUSIONS: Our results suggest that plasma BDNF does not represent a suitable candidate biomarker for determining the therapeutic response to ECT.
BACKGROUND:Brain derived neurotrophic factor (BDNF) has been implicated in the pathophysiology of depression and the antidepressant response. Electroconvulsive therapy (ECT) is reported to increase BDNF levels in blood, though only a small number of studies have been conducted to date. OBJECTIVE: Our objectives were to: 1) compare plasma BDNF levels in medicated patients with depression and controls; 2) assess the effect of ECT on plasma BDNF levels in medicated patients with depression; 3) explore the relationship between plasma BDNF levels and the Val66Met (rs6265) BDNF polymorphism; and 4) examine the relationship between plasma BDNF levels and clinical symptoms and outcomes with ECT. METHODS: Plasma BDNF levels were analyzed in samples from 61 medicated patients with a major depressive episode and 50 healthy controls, and in patient samples following a course of ECT. Fifty-two samples from the depressedpatient group were genotyped for the Val66MetBDNF polymorphism. RESULTS: There was no difference in plasma BDNF levels between the control and depressed groups, and there was no difference in plasma BDNF levels in patients following treatment with ECT. In line with previous reports, we show that, in medicated patients with depression, Met-carriers had higher plasma BDNF levels than Val-carriers, though genotype was not related to clinical response. We found no association between plasma BDNF levels and depression severity or the clinical response to ECT. CONCLUSIONS: Our results suggest that plasma BDNF does not represent a suitable candidate biomarker for determining the therapeutic response to ECT.
Authors: Elisabeth Maria van Zutphen; Didi Rhebergen; Eric van Exel; Mardien Leoniek Oudega; Filip Bouckaert; Pascal Sienaert; Matthieu Vandenbulcke; Max Stek; Annemieke Dols Journal: Transl Psychiatry Date: 2019-05-24 Impact factor: 6.222
Authors: T Vanicek; G S Kranz; B Vyssoki; A Komorowski; G Fugger; A Höflich; Z Micskei; S Milovic; R Lanzenberger; A Eckert; S Kasper; R Frey Journal: Acta Psychiatr Scand Date: 2019-09-11 Impact factor: 6.392
Authors: Beatrice Arosio; Franca Rosa Guerini; Richard C Oude Voshaar; Ivan Aprahamian Journal: Front Behav Neurosci Date: 2021-02-12 Impact factor: 3.558